Chimeric antigen receptor (CAR) T cell therapy is a type of immunotherapy treatment that uses genetically modified immune cells, known as T-cells, to locate and destroy cancer cells. The altered gene therapy is approved for use in patients with advanced, difficult-to-treat, or reoccurring lymphoma, leukemia, and multiple myeloma blood cancers.
There are currently six FDA-approved treatments among the drug class, which include Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel), and Yescarta (axicabtagene ciloleucel). These treatments were approved under the requirement that the FDA conduct a 15-year observational study to assess the potential for long-term adverse health outcomes and secondary malignancies that could occur after treatment.
However, in January, the U.S. Food and Drug Administration (FDA) ordered several manufacturers to add black box warnings to all CAR-T drugs, indicating that the side effects may increase the risk of T-cell malignancies, which can result in hospitalization and death. The decision came after the agency’s researchers found 22 cases of secondary cancer linked to CAR-T side effects.
Every day (but July 4th) right here.
https://www.barnhardtmemes.com
🥳💥👍
🥳🎯🤣
CAR-T Clinical Trial Results Indicate 60% of Patients Suffered Adverse Effects, Including One Patient Death
https://www.aboutlawsuits.com/car-t-clinical-trial-results-in-60-of-patients-suffering-adverse-effects-one-patient-death/
Chimeric antigen receptor (CAR) T cell therapy is a type of immunotherapy treatment that uses genetically modified immune cells, known as T-cells, to locate and destroy cancer cells. The altered gene therapy is approved for use in patients with advanced, difficult-to-treat, or reoccurring lymphoma, leukemia, and multiple myeloma blood cancers.
There are currently six FDA-approved treatments among the drug class, which include Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel), and Yescarta (axicabtagene ciloleucel). These treatments were approved under the requirement that the FDA conduct a 15-year observational study to assess the potential for long-term adverse health outcomes and secondary malignancies that could occur after treatment.
However, in January, the U.S. Food and Drug Administration (FDA) ordered several manufacturers to add black box warnings to all CAR-T drugs, indicating that the side effects may increase the risk of T-cell malignancies, which can result in hospitalization and death. The decision came after the agency’s researchers found 22 cases of secondary cancer linked to CAR-T side effects.
Abigail, thanks for the restack, reading, and comments. It is very appreciated.
Hilarious except that last one is so full of error I don’t know where to start...🤦🏼♂️
Thanks for the restack, it is appreciated.
my 2 most favorite ones:
1) "open box before eating pizza"
2) the one about the transgenders in nursing homes in 50 yrs.
Pure gold!
Love it
My favorite meme.
https://i.imgur.com/Lb3TdCT.jpg
Jim, I appreciate the restack, as well as the reading. Thank you, Sir.